HOBOKEN, N.J., Oct. 14 /PRNewswire/ — Octapharma
USA is accepting applications for the Octapharma
25th Anniversary Grants Program, which supports clinical or
pre-clinical research focused on human protein therapies in
coagulation disorders, immune therapy, intensive care and emergency
medicine. The application deadline is April 1, 2011.
Octapharma AG, one of the
largest human protein products manufacturers in the world, launched
the Octapharma Grants program last year in celebration of the
biopharmaceutical company’s 25th anniversary. The company’s first
ever grants program is only available to researchers based in the
United States and is administered by Octapharma
Earlier this year, the Rush
Hemophilia & Thrombophilia Center at Rush University Medical
Center in Chicago was awarded the first grant in the Octapharma
program to support research into blood induced joint damage in
Grant applications are accepted online only at www.octapharmagrants.com.
All grant requests will be evaluated by the Octapharma Grants
Committee and grant recipients will be announced shortly afterward.
Please visit www.octapharmagrants.com
for a complete description of the grants program, including the
application and review process.
About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma AG
is one of the largest human protein products manufacturers in the
world and has been committed to patient care and medical innovation